pubmed-article:12117602 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:12117602 | lifeskim:mentions | umls-concept:C1257890 | lld:lifeskim |
pubmed-article:12117602 | lifeskim:mentions | umls-concept:C0013819 | lld:lifeskim |
pubmed-article:12117602 | lifeskim:mentions | umls-concept:C0034721 | lld:lifeskim |
pubmed-article:12117602 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
pubmed-article:12117602 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
pubmed-article:12117602 | lifeskim:mentions | umls-concept:C0243192 | lld:lifeskim |
pubmed-article:12117602 | lifeskim:mentions | umls-concept:C0037322 | lld:lifeskim |
pubmed-article:12117602 | lifeskim:mentions | umls-concept:C1415306 | lld:lifeskim |
pubmed-article:12117602 | lifeskim:mentions | umls-concept:C0456962 | lld:lifeskim |
pubmed-article:12117602 | lifeskim:mentions | umls-concept:C0765373 | lld:lifeskim |
pubmed-article:12117602 | pubmed:issue | 2 | lld:pubmed |
pubmed-article:12117602 | pubmed:dateCreated | 2002-7-15 | lld:pubmed |
pubmed-article:12117602 | pubmed:abstractText | Studies of ionotropic receptors indicate that glutamate (Glu) neurotransmission plays a role in sleep. Here, we show for the first time that metabotropic 2/3 Glu (mGlu2/3) receptors play an active or permissive role in the control of REM sleep. The potent, selective, and systemically active mGlu2/3 receptor agonist LY379268 was administered systemically in doses of 1.0 and 0.25 mg/kg sc. The drug produced a dose-dependent suppression of rapid eye movement (REM) sleep and fast (10-50 Hz) EEG in non-rapid eye movement (NREM) sleep. The 1.0-mg/kg effect on REM sleep was remarkably powerful: REM sleep was totally suppressed in the 6-h postinjection and reduced by 80% in the next 6 h. NREM duration was unchanged during the REM suppression in spite of the strong and unusual depression of EEG power in fast NREM frequencies. These sleep and EEG effects were unaccompanied by motor or behavioral abnormalities. We hypothesize that the REM and the fast EEG suppression were both caused by a depression of brain arousal levels by LY379268. If correct, depressing arousal by reducing excitatory neurotransmission with an mGlu2/3 receptor agonist produces electrophysiological effects that differ drastically from those produced by depressing arousal by enhancing neural inhibition with GABAergic drugs. This different approach to modifying the excitation/inhibition balance in the brain might yield novel therapeutic actions. | lld:pubmed |
pubmed-article:12117602 | pubmed:language | eng | lld:pubmed |
pubmed-article:12117602 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12117602 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:12117602 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12117602 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12117602 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12117602 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12117602 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12117602 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12117602 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12117602 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:12117602 | pubmed:month | Sep | lld:pubmed |
pubmed-article:12117602 | pubmed:issn | 0091-3057 | lld:pubmed |
pubmed-article:12117602 | pubmed:author | pubmed-author:AndersonKK | lld:pubmed |
pubmed-article:12117602 | pubmed:author | pubmed-author:FeinbergII | lld:pubmed |
pubmed-article:12117602 | pubmed:author | pubmed-author:SchoeppD DDD | lld:pubmed |
pubmed-article:12117602 | pubmed:author | pubmed-author:CampbellI GIG | lld:pubmed |
pubmed-article:12117602 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:12117602 | pubmed:volume | 73 | lld:pubmed |
pubmed-article:12117602 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:12117602 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:12117602 | pubmed:pagination | 467-74 | lld:pubmed |
pubmed-article:12117602 | pubmed:dateRevised | 2003-11-14 | lld:pubmed |
pubmed-article:12117602 | pubmed:meshHeading | pubmed-meshheading:12117602... | lld:pubmed |
pubmed-article:12117602 | pubmed:meshHeading | pubmed-meshheading:12117602... | lld:pubmed |
pubmed-article:12117602 | pubmed:meshHeading | pubmed-meshheading:12117602... | lld:pubmed |
pubmed-article:12117602 | pubmed:meshHeading | pubmed-meshheading:12117602... | lld:pubmed |
pubmed-article:12117602 | pubmed:meshHeading | pubmed-meshheading:12117602... | lld:pubmed |
pubmed-article:12117602 | pubmed:meshHeading | pubmed-meshheading:12117602... | lld:pubmed |
pubmed-article:12117602 | pubmed:meshHeading | pubmed-meshheading:12117602... | lld:pubmed |
pubmed-article:12117602 | pubmed:meshHeading | pubmed-meshheading:12117602... | lld:pubmed |
pubmed-article:12117602 | pubmed:meshHeading | pubmed-meshheading:12117602... | lld:pubmed |
pubmed-article:12117602 | pubmed:meshHeading | pubmed-meshheading:12117602... | lld:pubmed |
pubmed-article:12117602 | pubmed:meshHeading | pubmed-meshheading:12117602... | lld:pubmed |
pubmed-article:12117602 | pubmed:meshHeading | pubmed-meshheading:12117602... | lld:pubmed |
pubmed-article:12117602 | pubmed:meshHeading | pubmed-meshheading:12117602... | lld:pubmed |
pubmed-article:12117602 | pubmed:meshHeading | pubmed-meshheading:12117602... | lld:pubmed |
pubmed-article:12117602 | pubmed:meshHeading | pubmed-meshheading:12117602... | lld:pubmed |
pubmed-article:12117602 | pubmed:meshHeading | pubmed-meshheading:12117602... | lld:pubmed |
pubmed-article:12117602 | pubmed:meshHeading | pubmed-meshheading:12117602... | lld:pubmed |
pubmed-article:12117602 | pubmed:year | 2002 | lld:pubmed |
pubmed-article:12117602 | pubmed:articleTitle | The selective group mGlu2/3 receptor agonist LY379268 suppresses REM sleep and fast EEG in the rat. | lld:pubmed |
pubmed-article:12117602 | pubmed:affiliation | Department of Psychiatry, University of California at Davis, Davis, CA 95616, USA. ifeinberg@ucdavis.edu | lld:pubmed |
pubmed-article:12117602 | pubmed:publicationType | Journal Article | lld:pubmed |